AI Article Synopsis
- Non-islet cell tumor hypoglycemia (NICTH) is a rare condition linked to unusual insulin-like growth factor production, leading to severe low blood sugar levels.
- Two surgical cases involving large thoracic solitary fibrous tumors (SFT) are discussed, with one patient experiencing severe hypoglycemia four years after tumor removal, and another ten years after detection.
- Both underwent successful surgery with immediate normalization of glucose and hormone levels, highlighting that even benign tumors like SFT can cause life-threatening hypoglycemia, necessitating ongoing monitoring post-treatment.
Article Abstract
Non-islet cell tumor hypoglycemia (NICTH) is one of the paraneoplastic syndromes manifesting severe hypoglycemia caused by aberrant production of high-molecular-weight insulin-like growth factor 2 (big-IGF2). Two surgical cases of extremely large thoracic solitary fibrous tumors (SFT) with unusual history of NICTH are presented. One case manifested severe hypoglycemia after four years of the first complete surgical resection of the tumor with potential malignant transformation, and the other case showed severe hypoglycemia after ten years of the first detection of the tumor. Meticulous laboratory testing, including serum endocrinological tests and western immunoblotting before and after surgery was performed, and both cases were diagnosed as NICTH. Both patients underwent open thoracic surgery. The patients showed normal glucose and hormone levels immediately after the resection of responsible tumors with elevated blood insulin concentration. SFTs are generally considered benign; however, life-threatening hypoglycemia can happen regardless of treatment. Careful follow-up of the tumor growth is warranted.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1620/tjem.2024.J012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Smart Insulin Pen in Pregnant Women with Type 1 Diabetes: An Encouraging Case Series.
Healthcare (Basel)
December 2024
Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
The management of type 1 diabetes in pregnancy with new technologies is challenging. Sometimes the complexity of new-generation systems such as "continuous subcutaneous insulin infusion, CSII" and patient or provider preference do not allow their use, so women with type 1 diabetes in pregnancy continue to be treated with subcutaneous multiple-injection insulin therapy using pens. Smart insulin pens are new tools that allow for data collection on insulin dose and time of administration and have additional connectivity features.
View Article and Find Full Text PDFCase report: Kabuki syndrome and persistent hypoglycemia in neonates.
J Family Med Prim Care
December 2024
Faculty of Medicine, King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
The Kabuki syndrome (KS) is a rare congenital disease that has two different types, KS1 and KS2, with variant in epigenetic gene KMT2D and KDM6A, respectively. It is associated with multiple abnormalities such as (developmental delay, atypical facial features, cardiac anomalies, minor skeleton anomalies, genitourinary anomalies, and mild to moderate intellectual disability). This syndrome can lead to neonatal hypoglycemia that results from hyperinsulinemia and electrolyte abnormalities.
View Article and Find Full Text PDFPredictors of hypocalcemia among children admitted in the Emergency Pediatric Unit of the University of Maiduguri Teaching Hospital, Maiduguri, Nigeria.
Saudi Med J
January 2025
From the Department of Pediatrics (Imam, Musa), University of Maiduguri Teaching Hospital; from the Department of Pediatrics (Elechi, Rabasa), College of Medical Sciences, University of Maiduguri, Maiduguri; and from the Department of Pediatrics (Bakari), College of Medical Sciences, Modibo Adama University, Yola, Nigeria.
Objectives: To determine the prevalence and pattern of hypoglycemia among children admitted to the Emergency Pediatric Unit (EPU) at the University of Maiduguri Teaching Hospital, Maiduguri, Nigeria.
Methods: A cross-sectional study was conducted between February and September 2020. Blood glucose, along with other relevant laboratory investigations, was measured for each patient upon admission to the EPU using a point-of-care test glucometer (ACCU-CHEK with strips).
Benchmarking the clinical outcomes of Healthentia SaMD in chronic disease management: a systematic literature review comparison.
Front Public Health
January 2025
AstraZeneca SpA, Milano Innovation District (MIND), Milano, Italy.
Background: Software as a Medical Device (SaMD) and mobile health (mHealth) applications have revolutionized the healthcare landscape in the areas of remote patient monitoring (RPM) and digital therapeutics (DTx). These technological advancements offer a range of benefits, from improved patient engagement and real-time monitoring, to evidence-based personalized treatment plans, risk prediction, and enhanced clinical outcomes.
Objective: The systematic literature review aims to provide a comprehensive overview of the status of SaMD and mHealth apps, highlight the promising results, and discuss what is the potential of these technologies for improving health outcomes.
Prescriptions and Reimbursement of Glucagon Products for Severe Hypoglycemia in Medicaid.
JAMA
January 2025
Center for Pharmaceutical Policy and Prescribing, University of Pittsburgh, Pittsburgh, Pennsylvania.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!